Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData
In December 2022, the company successfully concluded raising a total of $309 million following positive topline data from the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
NASH treatment
Madrigal drug meets main goals in much-awaited NASH trial
The positive data sets the stage for the drug, resmetirom, to become the first treatment for NASH